Quick Answer
Barinthus Biotherapeutics plc. reported Research And Development Expense of $25.56 million for the year ending 2025.
- Barinthus Biotherapeutics plc. showed a decrease of -39.5% in Research And Development Expense from 2024 to 2025.
- This data is from Barinthus Biotherapeutics plc.'s annual report (Form 10-K), filed with the SEC on March 13, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 6 years of available data (2020 to 2025), Barinthus Biotherapeutics plc.'s Research And Development Expense has grown by 77.7%.
- Historical annual values: Fiscal year 2025: $25.56 million | Fiscal year 2024: $42.24 million | Fiscal year 2023: $44.87 million | Fiscal year 2022: $42.35 million | Fiscal year 2021: $20.37 million | Fiscal year 2020: $14.39 million.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: